Choosing the right drug for the right patient with steatohepatitis

Luis Antonio Díaz, Juan Pablo Arab
Nature Reviews Gastroenterology & Hepatology · Springer Nature · 2026-11-11 · DOI: 10.1038/s41575-026-01283-9

Аннотация

Nature Reviews Gastroenterology & Hepatology, Published online: 11 November 2026; doi:10.1038/s41575-026-01283-9 With resmetirom and semaglutide approved for non-cirrhotic steatohepatitis with fibrosis, new European guidance moves the question from whether to treat to whom to treat, and with what. The noninvasive, phenotype-driven framework of these guidelines will shape clinical practice, yet much of the recommendations rests on expert consensus rather than comparative or outcome data.

Читать у издателя →

Похожие статьи